Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RTW Biotech OpportunitiesLSE:RTW 41 Return-on-Tangible-Asset is 62.32% as of Dec. 2025, which is 168% above its 10-year median of 23.22. GuruFocus rates LSE:RTW with a GF Score™ of 41/100. The stock has 2 warning signs investors should review. Among 1,635 Asset Management companies, RTW Biotech Opportunities ranks better than 93.21% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. RTW Biotech Opportunities's annualizedNet Income for the quarter that ended in Dec. 2025 was $571.9 Mil. RTW Biotech Opportunities's average total tangible assets for the quarter that ended in Dec. 2025 was $917.6 Mil. Therefore, RTW Biotech Opportunities's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 62.32%.
The historical rank and industry rank for RTW Biotech Opportunities's Return-on-Tangible-Asset or its related term are showing as below:
LSE:RTW'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -14.96 Med: 23.22 Max: 50.46
Current: 28.34
During the past 8 years, RTW Biotech Opportunities's highest Return-on-Tangible-Asset was 50.46%. The lowest was -14.96%. And the median was 23.22%.
LSE:RTW's Return-on-Tangible-Asset is ranked better than 93.21% of 1635
companies
in the Asset Management industry
Industry Median: 4.23
vs LSE:RTW: 28.34
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
RTW Biotech Opportunities Return-on-Tangible-Asset Related Terms
RTW Biotech Opportunities Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for RTW Biotech Opportunities's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:RTW vs BLK, BX, KKR: Return-on-Tangible-Asset Comparison
For the Asset Management subindustry, RTW Biotech Opportunities's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RTW Biotech Opportunities Return-on-Tangible-Asset vs Asset Management Industry
For the Asset Management industry and Financial Services sector, RTW Biotech Opportunities's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where RTW Biotech Opportunities's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 62.32% mean?
RTW Biotech Opportunities (LSE:RTW) has a Return-on-Tangible-Asset of 62.32% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on RTW Biotech Opportunities and its competitors. This is 168% above median its historical median of 23.22. According to the industry distribution chart, RTW Biotech Opportunities ranks #111 out of 1635 companies in the Asset Management industry, placing it in the top 6.8%.
Is RTW Biotech Opportunities' Return-on-Tangible-Asset too high?
RTW Biotech Opportunities' current Return-on-Tangible-Asset of 62.32% is 168% above median its 10-year median of 23.22. The Asset Management industry median Return-on-Tangible-Asset is 4.23. RTW Biotech Opportunities' value of 62.32% is 1373.3% above this industry median. Based on the distribution chart, RTW Biotech Opportunities ranks #111 out of 1635 companies in the Asset Management industry, which is in the top quartile — a strong position relative to peers. Overall, RTW Biotech Opportunities has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' Return-on-Tangible-Asset compare to BLK and BX?
According to the Asset Management industry distribution chart, RTW Biotech Opportunities ranks #111 out of 1635 companies for Return-on-Tangible-Asset. This places RTW Biotech Opportunities in the top 7% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 4.23. RTW Biotech Opportunities' value of 62.32% is 1373.3% above this benchmark. While the company's 10-year median is 23.22 vs. the industry median of 4.23, RTW Biotech Opportunities has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for an Asset Management company?
The median Return-on-Tangible-Asset among Asset Management companies is 4.23, based on 1,635 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RTW Biotech Opportunities's current Return-on-Tangible-Asset of 62.32% is 1373.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on RTW Biotech Opportunities and its competitors. For the Asset Management industry, the median Return-on-Tangible-Asset is 4.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RTW Biotech Opportunities's current Return-on-Tangible-Asset is 62.32%, which is 168% above median its own 10-year median of 23.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current Return-on-Tangible-Asset of 62.32%. The current Return-on-Tangible-Asset is 62.32%, which is 168% above median its 10-year median of 23.22 and 1373.3% above the Asset Management industry median of 4.23. RTW Biotech Opportunities' overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current Return-on-Tangible-Asset is 62.32% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
41GF Score
Get the complete analysis for LSE:RTW
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:RTW has been successfully added to your 
